We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Anti-Tumor Efficiency of Perillylalcohol/β-Cyclodextrin Inclusion Complexes in a Sarcoma S180-Induced Mice Model.
- Authors
Rezende, Allan A.; Santos, Rafael S.; Andrade, Luciana N.; Amaral, Ricardo G.; Pereira, Matheus M.; Bani, Cristiane; Chen, Mo; Priefer, Ronny; da Silva, Classius F.; de Albuquerque Júnior, Ricardo L. C.; Souto, Eliana B.; Severino, Patrícia; Lauro, Maria Rosaria; Kojic, Milos
- Abstract
The low solubility and high volatility of perillyl alcohol (POH) compromise its bioavailability and potential use as chemotherapeutic drug. In this work, we have evaluated the anticancer activity of POH complexed with β-cyclodextrin (β-CD) using three complexation approaches. Molecular docking suggests the hydrogen-bond between POH and β-cyclodextrin in molar proportion was 1:1. Thermal analysis and Fourier-transform infrared spectroscopy (FTIR) confirmed that the POH was enclosed in the β-CD cavity. Also, there was a significant reduction of particle size thereof, indicating a modification of the β-cyclodextrin crystals. The complexes were tested against human L929 fibroblasts after 24 h of incubation showing no signs of cytotoxicity. Concerning the histopathological results, the treatment with POH/β-CD at a dose of 50 mg/kg promoted approximately 60% inhibition of tumor growth in a sarcoma S180-induced mice model and the reduction of nuclear immunoexpression of the Ki67 antigen compared to the control group. Obtained data suggest a significant reduction of cycling cells and tumor proliferation. Our results confirm that complexation of POH/β-CD not only solves the problem related to the volatility of the monoterpene but also increases its efficiency as an antitumor agent.
- Subjects
INCLUSION compounds; KI-67 antigen; SARCOMA; SIZE reduction of materials; PROBLEM solving; CYCLODEXTRIN derivatives
- Publication
Pharmaceutics, 2021, Vol 13, Issue 2, p245
- ISSN
1999-4923
- Publication type
Article
- DOI
10.3390/pharmaceutics13020245